Jan. 30 at 6:37 PM
$ENSC We understand desire for clear timelines, which is why we provided a mid-study enrollment update. The update is factual, not a projection.
As shared in yesterday’s update, PF614-301 began enrollment in late December and has now reached 50% of the subjects targeted for interim review. Reaching this level of enrollment early reflects active execution across clinical sites and moves the study closer to generating interim data.
As we focus on completing enrollment and ensuring data quality, we will provide further guidance when available. Thank you for your continued interest.
